Physician profile
Jonathan Bret Strober
NPI 1457454308
$163,711.40
in general payments reported to CMS, 2019-2025
18 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $17K · 2021: $11K · 2022: $27K · 2023: $22K · 2024: $9,370 · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $20K · Travel and Lodging: $8,773 · Food and Beverage: $3,464 · Honoraria: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,095.00 |
| Consulting Fee | $19,924.00 |
| Travel and Lodging | $8,772.75 |
| Food and Beverage | $3,463.54 |
| Honoraria | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $107,894.73 | 2019-2025 | Skyclarys, Spinraza, Spinraza |
| Sarepta Therapeutics, INC. | $17,818.24 | 2019-2025 | Elevidys |
| Janssen Scientific Affairs, LLC | $9,949.94 | 2025 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $7,290.77 | 2019-2022 | |
| Pfizer INC. | $6,000.00 | 2023-2024 | |
| Janssen Global Services, LLC | $3,533.64 | 2024-2025 | |
| Janssen Biotech, INC. | $3,494.18 | 2025 | |
| Alexion Pharmaceuticals, INC. | $3,083.23 | 2021-2022 | |
| Ns Pharma, INC. | $1,327.43 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $1,325.00 | 2025 | |
| Argenx US, INC. | $1,308.60 | 2022 | |
| Itf Therapeutics LLC | $597.96 | 2024-2025 | |
| Astellas Pharma US INC | $87.68 | 2025 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Strober listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.